Detalles de la búsqueda
1.
Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
Appl Health Econ Health Policy
; 16(4): 569-577, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29923173
2.
Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
J Med Econ
; 21(10): 960-967, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29898619
3.
Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.
Clinicoecon Outcomes Res
; 8: 475-484, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27703384
4.
Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting ß-agonists.
Appl Health Econ Health Policy
; 12(4): 447-59, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24974107
5.
Erratum to: Cost Effectiveness of Tiotropium in Patients with Asthma Poorly Controlled on Inhaled Glucocorticosteroids and Long-Acting ß-Agonists.
Appl Health Econ Health Policy
; 14(1): 119-25, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26816028
Resultados
1 -
5
de 5
1
Próxima >
>>